Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.
Animals
Antibodies, Monoclonal
/ pharmacology
Antineoplastic Agents
/ pharmacology
Cytokines
/ pharmacology
Endopeptidases
Humans
Immunotherapy
/ methods
Lymphocyte Activation
/ drug effects
Macaca mulatta
Membrane Proteins
/ antagonists & inhibitors
Mice
Neoplasms, Experimental
/ pathology
Recombinant Fusion Proteins
/ pharmacology
Xenograft Model Antitumor Assays
FAP-il2v
fibroblast activation protein
immunocytokine
interleukin-2
rg7461
Journal
mAbs
ISSN: 1942-0870
Titre abrégé: MAbs
Pays: United States
ID NLM: 101479829
Informations de publication
Date de publication:
Historique:
entrez:
11
5
2021
pubmed:
12
5
2021
medline:
29
12
2021
Statut:
ppublish
Résumé
Simlukafusp alfa (FAP-IL2v, RO6874281/RG7461) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAP) and an IL-2 variant with a retained affinity for IL-2Rβγ > IL-2 Rβγ and abolished binding to IL-2 Rα. Here, we investigated the immunostimulatory properties of FAP-IL2v and its combination with programmed cell death protein 1 (PD-1) checkpoint inhibition, CD40 agonism, T cell bispecific and antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. The binding and immunostimulatory properties of FAP-IL2v were investigated
Identifiants
pubmed: 33974508
doi: 10.1080/19420862.2021.1913791
pmc: PMC8115765
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antineoplastic Agents
0
Cytokines
0
Membrane Proteins
0
Recombinant Fusion Proteins
0
Endopeptidases
EC 3.4.-
fibroblast activation protein alpha
EC 3.4.21.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1913791Subventions
Organisme : NCI NIH HHS
ID : P30 CA012197
Pays : United States
Références
J Immunother Cancer. 2016 Oct 18;4:67
pubmed: 27777776
J Invest Dermatol. 2013 Mar;133(3):751-758
pubmed: 23096716
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3320-5
pubmed: 25733854
Proteomics Clin Appl. 2014 Jun;8(5-6):454-63
pubmed: 24470260
Cancer. 2008 Jul 15;113(2):293-301
pubmed: 18457330
Trends Immunol. 2015 Dec;36(12):763-777
pubmed: 26572555
Cancer Immunol Res. 2014 Jul;2(7):668-78
pubmed: 24906352
J Nucl Med. 2019 Jun;60(6):801-805
pubmed: 30954939
Nat Rev Immunol. 2012 Feb 17;12(3):180-90
pubmed: 22343569
Nat Immunol. 2005 Nov;6(11):1142-51
pubmed: 16227984
J Immunol. 2014 Jun 15;192(12):5451-8
pubmed: 24907378
Mol Cancer Ther. 2012 Feb;11(2):257-66
pubmed: 22323494
Clin Cancer Res. 2016 Feb 1;22(3):680-90
pubmed: 26832745
J Nucl Med. 2021 Feb;62(2):160-167
pubmed: 33127618
Nature. 2014 May 29;509(7502):541-2
pubmed: 24870520
Lancet Oncol. 2018 May;19(5):694-704
pubmed: 29628312
Cancer Biol Ther. 2012 Feb 1;13(3):123-9
pubmed: 22236832
Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15105-10
pubmed: 20696918
J Clin Oncol. 2004 Nov 15;22(22):4463-73
pubmed: 15483010
Gut. 2018 Feb;67(2):320-332
pubmed: 27797936
Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11906-11
pubmed: 20547866
Clin Cancer Res. 2015 Feb 1;21(3):561-8
pubmed: 25424850
Nat Immunol. 2005 Nov;6(11):1152-9
pubmed: 16227983
Cancer Immunol Immunother. 2015 Aug;64(8):999-1009
pubmed: 25971540
J Nucl Med. 2012 Jan;53(1):113-20
pubmed: 22213822
Curr Med Chem. 2010;17(29):3297-302
pubmed: 20712575
Oncoimmunology. 2016 Apr 25;5(6):e1163462
pubmed: 27471638
Clin Cancer Res. 2001 Sep;7(9):2862-9
pubmed: 11555604
J Nucl Med. 2015 May;56(5):778-83
pubmed: 25858044
J Clin Oncol. 2010 Nov 20;28(33):4969-75
pubmed: 20921469
Clin Cancer Res. 2016 Jul 1;22(13):3286-97
pubmed: 26861458
BMC Cancer. 2013 Jan 15;13:20
pubmed: 23320927
Clin Cancer Res. 2008 Sep 1;14(17):5610-8
pubmed: 18765555
Immunology. 2001 Aug;103(4):426-34
pubmed: 11529932
Nat Immunol. 2005 Nov;6(11):1071-2
pubmed: 16239920
Clin Cancer Res. 2002 Jan;8(1):210-6
pubmed: 11801561
Oncoimmunology. 2016 Jun 24;5(8):e1203498
pubmed: 27622073
Immunity. 1998 May;8(5):615-23
pubmed: 9620682
MAbs. 2011 Sep-Oct;3(5):422-30
pubmed: 22048693
MAbs. 2011 Jan-Feb;3(1):61-6
pubmed: 20962582
Oncoimmunology. 2017 Jan 11;6(3):e1277306
pubmed: 28405498